Company / Return on Equity (ROE)
Prime Medicine, Inc. Return on Equity (ROE) History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-127.9%
FY2024
5-year range
-148.9% / -38.5%
FY2020-FY2024
Trend
+14.1%
vs FY2023
Sector context
#172 of 190
Health Care
What the data says
Prime Medicine, Inc. reports negative total equity of -127.9% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-127.9% in FY2024.
Declined from -38.5% to -127.9% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 190This company -127.9% Sector average -29.0%
▼
-341.8% below sector average
Key checks
Key Insights
- In FY2024, return on equity (roe) increased 14.1% year-over-year.
- Currently 98.9pp below the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score -1.24 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -127.9% | +14.1% |
| FY2023 | -148.9% | -286.5% |
| FY2022 | -38.5% | - |
| FY2021 | - | - |
| FY2020 | -145.8% | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026